Cytogenetics Market size is valued at USD 2.5 billion in 2021 and is poised to grow at a significant CAGR of 9.8% over 2022–2028. Bridging the gap between clinical applications of genetic results and offering an advanced medical service is the most crucial aim of human genetics. The adoption of cytogenetic techniques is directly impacted by the growth in the use of genetic information in predictive models for disease features, increasing income-generating. The market has been considerably pushed by rising cancer mortality rates and the associated increase in cancer incidence. The ongoing increase in cancer cases has highlighted the requirement for creating cutting-edge technology for a thorough understanding of cancer at the genomic level. Furthermore, the most well-known cytogenetic methods include FISH and CGH, which offer comprehensive details on the molecular signatures of cancer. These techniques help with gaining an understanding of how cancer develops. As several cytogenetic procedures have been effectively used for pharmacogenomic biomarker investigations, expanding pharmacogenomics activities are predicted to impact market growth significantly. A sizable number of published studies proving the function of cytogenetic methods in pharmacogenomic testing demonstrate the practical application of CGH, FISH, and sequencing technology in pharmacogenomics. The application range of cytogenetics techniques has been expanded due to ongoing improvements in CGH and FISH regarding resolution and specificity in basic research and molecular diagnostics. These developments have effectively overcome the limits of traditional cytogenetic analysis. Moreover, it is anticipated that the worldwide cytogenetics market will expand in the upcoming years due to an increase in health care spending, the prevalence of chronic diseases, and a favorable reimbursement environment. Additionally, market players use cutting-edge methods and tactics to develop original approaches to cytogenetic analysis, which is predicted to drive the market. However, emerging markets are anticipated to offer the industry excellent market possibilities during the projection period.
Recent Market Developments:
In March 2020, Agilent Technologies Inc. launched three new microarrays to meet the requirement of cytogenetics laboratories that conduct prenatal and postnatal research.